Participating Faculty: Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 UpdateNovember 1st 2022
Introduction to Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 UpdateBySonia T. Oskouei, PharmDNovember 1st 2022
Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current EvidenceByVibeke Strand, MD,Colby Evans, MD,Allan Gibofsky, MD, JDNovember 1st 2022
Biosimilar medicines: what are they and how are they used?ByVibeke Strand, MD,Colby Evans, MD,Allan Gibofsky, MD, JDNovember 1st 2022Plain Language Summary
Provider and Patient Knowledge Gaps on Biosimilars: Insights From SurveysByAllan Gibofsky, MD, JD,Colby Evans, MD,Vibeke Strand, MDNovember 1st 2022
What do patients and health care providers still need to know about biosimilar medicines?ByAllan Gibofsky, MD, JD,Colby Evans, MD,Vibeke Strand, MDNovember 1st 2022Plain Language Summary
eAppendix: Provider and Patient Knowledge Gaps on Biosimilars: Insights From SurveysByAllan Gibofsky, MD, JD,Colby Evans, MD,Vibeke Strand, MDNovember 1st 2022
Biosimilars for Immune-Mediated Inflammatory Diseases – A Managed Care PerspectiveByColby Evans, MD,Allan Gibofsky, MD, JD,Vibeke Strand, MDNovember 1st 2022
What are the current challenges to wider biosimilar use in the United States?ByColby Evans, MD,Allan Gibofsky, MD, JD,Vibeke Strand, MDNovember 1st 2022Plain Language Summary
